Research programme: benign prostatic hyperplasia therapy - Bayer/Millennium
Alternative Names: Benign prostatic hyperplasia therapy research programme - Bayer/MillenniumLatest Information Update: 30 Jun 2006
At a glance
- Originator Bayer; Millennium Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 31 Dec 2005 No development reported - Preclinical for Benign prostatic hyperplasia in Germany (unspecified route)
- 31 Dec 2005 No development reported - Preclinical for Benign prostatic hyperplasia in USA (unspecified route)
- 08 Dec 2003 This programme is still in active development